sorafenib has been researched along with pd 173074 in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pd 173074) | Trials (pd 173074) | Recent Studies (post-2010) (pd 173074) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 160 | 0 | 106 |
| Protein | Taxonomy | sorafenib (IC50) | pd 173074 (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | 0.028 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.0217 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.028 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.19 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.013 | |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | 0.5337 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.0268 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.19 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.1325 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
3 other study(ies) available for sorafenib and pd 173074
| Article | Year |
|---|---|
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Protein Kinase Inhibitors | 2007 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |